Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01554618 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 84
- Enrollment target
NCT01554618: Completed Phase 3 study, sponsored by AstraZeneca.
NCT01554618 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 84 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01554618, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 84 participants
- Enrollment target
Study Summary
The study examines the Safety and efficacy study of exenatide once weekly in children and adolescents with type 2 diabetes
Primary Outcome
Change from baseline in HbA1c (%) to Week 24 during the controlled assessment period is reported as adjusted least square (LS) mean values. Baseline was defined as the last non-missing assessment (scheduled or unscheduled) on or prior to the first dose of randomized study medication. A mixed model with repeated measures (MMRM) analysis was performed, excluding data collected after initiation of rescue medication or premature discontinuation of study medication.
Interventions
- DRUG Placebo
- DRUG Exenatide Once Weekly
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2011-12-02 |
| Est. Completion | 2021-05-05 |
| Phase | Phase 3 |
What the finished NCT01554618 record still lists
NCT01554618 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01554618 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01554618 about?
NCT01554618 is a clinical study titled "Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes". The study examines the Safety and efficacy study of exenatide once weekly in children and adolescents with type 2 diabetes
What is the current status of trial NCT01554618?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 84 participants. The study started on 2011-12-02. Estimated completion is 2021-05-05.
What interventions are being tested in trial NCT01554618?
The interventions under investigation include: Placebo (DRUG), Exenatide Once Weekly (DRUG).
Who is sponsoring clinical trial NCT01554618?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01554618's enrollment target sits among peer trials
84 1749th of 2000 higher than 250 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI